subscribeSubscribe
Renalys Submits an IND App for a Ph III Trial of sparsentan for IgA Nephropathy

Renalys Submits an IND App for a Ph III Trial of sparsentan for IgA Nephropathy
PR NEWSWIRE
07 Apr 2024
Share Share
Travere to Present Abstracts on FILSPARI in IgA Nephropathy at World Congress

Travere to Present Abstracts on FILSPARI in IgA Nephropathy at World Congress
GLOBENEWSWIRE
03 Apr 2024
Share Share
Travere Submits sNDA to the FDA Seeking Full Approval of FILSPARI

Travere Submits sNDA to the FDA Seeking Full Approval of FILSPARI
GLOBENEWSWIRE
11 Mar 2024
Share Share
Travere drug for rare kidney condition recommended for EU approval

Travere drug for rare kidney condition recommended for EU approval
REUTERS
24 Feb 2024
Share Share
Travere`s Filspari misses the mark in rare kidney disease trial

Travere`s Filspari misses the mark in rare kidney disease trial
Fraiser Kansteiner FIERCE PHARMA
22 Sep 2023
Share Share
Travere Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI

Travere Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI
GLOBENEWSWIRE
21 Sep 2023
Share Share
Travere fails to beat off-label blood pressure drug in phase 3

Travere fails to beat off-label blood pressure drug in phase 3
Nick Paul Taylor FIERCE BIOTECH
03 May 2023
Share Share
Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Ph 3 DUPLEX

Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Ph 3 DUPLEX
PR NEWSWIRE
02 May 2023
Share Share
Travere Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI

Travere Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI
GLOBENEWSWIRE
01 Apr 2023
Share Share
Travere turns BMS castoff into rare kidney disease approval

Travere turns BMS castoff into rare kidney disease approval
Angus Liu FIERCE PHARMA
18 Feb 2023
Share Share